Heron Therapeutics (NASDAQ:HRTX)’s share price plunged -3.36% or -0.55 to reach at $15.8 during previous trading session. A total of 883410 shares exchanged hands, whereas the company’s average trading volume stands at 707.85 Million shares. Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $913.87 Million and most recently 57.84 Million outstanding shares have been calculated.

According to sentiments of 11 analysts the mean estimates of short term price target for the company’s stock is marked at $30.36. The most optimistic analyst sees the stock reaching $42 while the most conventional predicts the target price at $25.

In terms of Buy/Sell recommendations, 8 analysts have a consensus rating of 1.13 on the shares of Heron Therapeutics (NASDAQ:HRTX). Out of rating recommendations 4 have given the stock a Buy while 8 recommend the stock as Outperform. 0 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

Heron Therapeutics (NASDAQ:HRTX)’s distance from 20 day simple moving average is 0.0111 along with distance from 50 day simple moving average of 16.33 whereas its distance from 200 day simple moving average is 15.31. Heron Therapeutics (NASDAQ:HRTX)’s price distance from 52-week high is -24.22 and from 52-week low is 29.37. The stock hit its 52-week high price on 11/16/16, and 52-week low price on 01/12/17. The stock’s 52-week price fluctuated within the range of $20.85 – $12.21.

Heron Therapeutics (NASDAQ:HRTX)’s shares slipped -1.56% in the past week and soared 2.6% in the last 4 weeks, historically the stock illustrate that its six months performance stands at 10.49% while its year to date performance is at 20.61%.

While taking a glance at financials, we can look at a number of key indicators. Heron Therapeutics (NASDAQ:HRTX) has a Return on Assets (ROA) of -141.4. The company currently has a Return on Equity (ROE) of -385.1 and a Return on Investment (ROI) of -540.9. Average true range (ATR-14) of the company sets at 0.85, along with its weekly and monthly volatility of 5.92% and 5.31% respectively. Relative strength index (RSI-14) for Heron Therapeutics (NASDAQ:HRTX) is at 49.9. Beta value of the stock stands at 2.06.

The company’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 2 along with current ratio for most recent quarter of 2.1. Total debt to equity ratio of Heron Therapeutics (NASDAQ:HRTX) for most recent quarter is 0.71 whereas long term debt to equity ratio for most recent quarter is 0.62.

Shares of Capstead Mortgage Corp (NYSE:CMO) soared 0.92% or 0.08 to reach at $8.82 during previous trading session. Capstead Mortgage Corp (NYSE:CMO) has a market capitalization of $850.51 Million and most recently 96.43 Million outstanding shares have been calculated. A total of 883213 shares exchanged hands, whereas the company’s average trading volume stands at 620.74 Million shares.

According to 2 analysts Capstead Mortgage Corp (NYSE:CMO)’s price will reach at $9 during 52 weeks. Stock’s minimum price target estimates has been figured out at $8 while the maximum price target forecast is established at $10.

Shares of Capstead Mortgage Corp (NYSE:CMO) climbed 2.2% in the past week and plunged -8.88% in the last 4 weeks, historically the stock illustrate that its six months performance stands at -15.84% while its year to date performance is at -13.44%.

Capstead Mortgage Corp (NYSE:CMO)’s 52-week price fluctuated within the range of $11.41 – $8.52. Its price distance from 52-week high is -22.7 and from 52-week low is 3.52. The stock hit its 52-week high price on 05/01/17, and 52-week low price on 11/06/17. Capstead Mortgage Corp (NYSE:CMO)’s distance from 20 day simple moving average is-0.0347 along with distance from 50 day simple moving average of 9.38 whereas its distance from 200 day simple moving average is 10.02.

Total debt to equity ratio of Capstead Mortgage Corp (NYSE:CMO) for most recent quarter is 12.29 whereas long term debt to equity ratio for most recent quarter is 0.1. The company’s price to free cash flow for trailing twelve months is 3.99. Its quick ratio for most recent quarter is 0 along with current ratio for most recent quarter of 0.

Average true range (ATR-14) of the company sets at 0.14, along with its weekly and monthly volatility of 1.31% and 1.71% respectively. Relative strength index (RSI-14) for Capstead Mortgage Corp (NYSE:CMO) is at 35.7. Beta value of the stock stands at 0.35. Capstead Mortgage Corp (NYSE:CMO) has a Return on Assets (ROA) of 0.4. The company currently has a Return on Equity (ROE) of 5.6 and a Return on Investment (ROI) of 0.6.